Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon May 31, 2023 9:12am

176 Views

Post# 35472042

RE:RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

Thanks NotinKansas.
My problem is my brain does not work in that fashion. The chart on the left side represents to me that there are 58 patients being tracked. I would like to think that they are Patients #1 to Patient #58 by order of enrolment -- to me that is straight forward - and the bottom of the chart kind of suggests that, by the arrows depicting the time frames. ie. Patients #54 - #58 have just embarked on their journey.
To-date (of last posting on the chart) there are only 39 patients that have fully reached the 360 & 450 day time periods.

You suggest that patients are moving up and down the chart as a matter of ranking and not just across the chart - what is the purpose or necessity of doing that? Why doesn't Patient #1 remain Patient #1, Patient #15 remain Patient #15, and so forth? Would it not be so much easier for laymen to follow any given Patient's path from start to finish and prevent 100 different analyses by our members of what is happening each time a report comes out.

Maybe my brain works too simple and tries to simplify as opposed to making something too complex for what it is.

Thanks anyway -- I'll just continue to follow along.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects